Home > Inhibitors & Agonists > PI3K/Akt/mTOR > Akt
Cat. No. Product name CAS No.
DC5163 A-674563 Featured

A-674563 is a potent, orally available Akt1 inhibitor with an IC50 value of 11nM. Also displays activity against PKA and CDK2 with IC50 values of 16nM and 46nM respectively.

552325-73-2
DC7994 Afuresertib HCl Featured

Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM).

1047645-82-8
DC8411 Afuresertib Featured

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

1047644-62-1
DC8458 Akt Inhibitor VIII Featured

Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity (IC50 = 58 nM, 210 nM, and 2.12 μM; respectively).

612847-09-3
DC8695 Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.

893422-47-4
DC9972 ARQ-092 Featured

ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).

1313881-70-7
DC9336 AT7867 (dihydrochloride)

AT7867 Hcl is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.

1431697-86-7
DC9335 AT7867

AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.

857531-00-1
DC10408 BAY1125976

BAY1125976 is a selective allosteric Akt1/2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

1402608-02-9
DC10974 Ch-319

Ch-319 (Ch319) is a triphenyltin (IV) carboxylate derivative that modulates AKT/FOXO3a signaling and inhibits progression of prostate cancer.

DC2070 pan-Akt inhibitor GS690693

GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively.

937174-76-0
DC7465 MK-2206 2HCl Featured

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

1032350-13-2
DC2021 Perifosine (KRX-0401) Featured

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM.

157716-52-4
DC7481 PHT427

PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively.

1191951-57-1
DC9273 SC-66 Featured

SC-66 is an allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination.

871361-88-5
DC8333 SC-79 Featured

SC-79 is an activator of Akt; binds to the pleckstrin homology domain of Akt.

305834-79-1
DC10055 Akt-I-1,2 HCl Featured

The compound (Akt-I-1,2) inhibited both Akt1 and Akt2 with IC50 values of 2.7 and 21 μM respectively.

473382-50-2
DC28979 FPA-124

FPA-124, a cell-permeable copper complex, is a selective Akt inhibitor with an IC50 of 0.1 μM. FPA-124 interacts with both the pleckstrin homology (PH) and the kinase domains of Akt. FPA-124 induces apoptosis.

902779-59-3
Page 1 / Total 1 FirstPrevNextLastGoto